GlassScriptPhysician profile
Kevin E Anderson
NPI 1942202916
$6,352.04
in general payments reported to CMS, 2019-2025
39 companies · $1,994 in 2025
The $1,994 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $950 · 2020: $179 · 2021: $308 · 2022: $1,121 · 2023: $927 · 2024: $872 · 2025: $1,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,819 · Consulting Fee: $975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,818.57 |
| Consulting Fee | $975.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $987.73 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Shionogi INC | $975.00 | 2025 | S-217622 |
| Novo Nordisk INC | $571.09 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $516.52 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.73 | 2019-2025 | Jardiance, Synjardy |
| Pinnacle, INC | $409.85 | 2022 | |
| Astellas Pharma US INC | $309.97 | 2019-2025 | Veozah |
| Lilly USA, LLC | $288.74 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $284.38 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $238.49 | 2019-2025 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $215.44 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $125.89 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $81.71 | 2019-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $68.44 | 2019-2025 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $62.77 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $60.80 | 2021-2022 | |
| Radius Health, INC. | $51.28 | 2019-2024 | Tymlos |
| Dexcom, INC. | $49.39 | 2023-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $47.60 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.23 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $41.81 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $41.27 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $40.96 | 2019-2020 | |
| Medtronic, INC. | $37.54 | 2023 | Closurefast |
| Antares Pharma, INC. | $34.80 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Sumitomo Pharma America, INC. | $32.88 | 2024 | Gemtesa |
| Indivior INC. | $31.87 | 2024 | Sublocade |
| Allergan, INC. | $26.93 | 2019 | |
| Collegium Pharmaceutical, INC. | $25.77 | 2019 | |
| Corium, LLC | $25.24 | 2025 | Azstarys |
| Lundbeck LLC | $24.59 | 2024 | Rexulti |
| Verona Pharma, INC. | $24.31 | 2025 | Ohtuvayre |
| Neurelis, INC. | $19.84 | 2024 | Valtoco |
| Aimmune Therapeutics, INC. | $19.48 | 2024 | |
| Corcept Therapeutics | $18.17 | 2025 | Korlym |
| Neurocrine Biosciences, INC. | $15.76 | 2023 | Ingrezza |
| Abbott Laboratories | $13.20 | 2022 | |
| Mylan Specialty L.P. | $11.30 | 2019 | |
| Amarin Pharma, INC. | $11.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.